News > Novavax exec says its new COVID shot should work against variants on the rise

Novavax exec says its new COVID shot should work against variants on the rise

Novavax Inc's Head of R&D said an updated COVID-19 vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulation in the US. Protein-based vaccines like Novavax's take longer to produce than the messenger RNA-based (mRNA) versions made by Moderna and Pfizer/BioNTech. Hence, the company began producing a vaccine to target the currently dominant XBB.1.5 variant of the virus at a commercial scale.